Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Hospira

- PMLiVE

Pfizer and viral infection specialist ReViral agree on $525m deal

According to the deal, Pfizer will acquire ReViral for a total of up to $525m

- PMLiVE

Novartis restructures organisation to support growth and innovation

The new operational structure will involve integrating pharmaceuticals and oncology business units into an Innovative Medicines business

- PMLiVE

Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis

In the UK, almost four million people are affected by osteoporosis, resulting in around 520,000 fragility fractures each year

- PMLiVE

FDA grants Pfizer/BioNTech expanded EUA for an additional COVID-19 vaccine booster

The second booster authorisation is for those aged 50 years and older to promote high levels of protection against COVID-19 in the most vulnerable groups

- PMLiVE

Amgen shares new Otezla data at American Academy of Dermatology congress 2022

Around 125 million people worldwide have psoriasis, including an estimated 14 million people in Europe

- PMLiVE

Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients

There are an estimated 130,000 people with MS in the UK

- PMLiVE

FDA approves Novartis’ Pluvicto for prostate cancer

The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients

- PMLiVE

Pfizer receives Breakthrough Therapy Designation from FDA for RSV vaccine candidate

There are currently no preventative, therapeutic or vaccine options for older adults diagnosed with RSV

- PMLiVE

Pfizer agrees to supply UNICEF with up to 4 million courses of oral COVID-19 treatments

The deal is set to benefit to 95 low- and middle-income countries, pending authorisation or approval

- PMLiVE

Pfizer highlights need for fourth dose of COVID-19 vaccine to FDA

While new study published in The Lancet shows COVID-19 mortality rate is almost three times higher than previously thought

- PMLiVE

Pfizer finalises $6.7bn acquisition of Arena Pharmaceuticals

Arena is a clinical stage company developing innovative potential therapies for immuno-inflammatory diseases

- PMLiVE

Pfizer begins phase 2/3 study of oral COVID-19 treatment in paediatric patients

The phase 2/3 trial involves around 140 patients under the age of 18

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links